From the Nuclear Medicine Department, University Hospital of Bordeaux and INCIA, University of Bordeaux.
Departments of Urology.
Clin Nucl Med. 2019 Sep;44(9):e535-e536. doi: 10.1097/RLU.0000000000002672.
Ga-labeled prostate-specific membrane antigen inhibitors and Ga-labeled gastrin-releasing peptide receptor antagonists showed interesting results for staging biochemically recurrent prostate cancer. In this case, Ga-prostate-specific membrane antigen-617 PET/CT, Ga-RM2 PET/CT, and F-choline PET/CT were performed in a patient (66-year-old man, prostate-specific antigen = 6.7 ng/mL) with biopsy-proven Gleason 9 (5 + 4) prostate cancer, candidate for radical prostatectomy and lymph node dissection.
镓标记的前列腺特异性膜抗原抑制剂和镓标记的胃泌素释放肽受体拮抗剂在分期生化复发前列腺癌方面显示出有趣的结果。在这种情况下，对一名经活检证实患有前列腺癌（Gleason 评分 9[5+4]）、适合接受根治性前列腺切除术和淋巴结清扫术的 66 岁男性患者进行了 Ga-前列腺特异性膜抗原-617 PET/CT、Ga-RM2 PET/CT 和 F-胆碱 PET/CT 检查。
